Introduction
Approximately 30% of patients with hemophilia develop neutralizing inhibitory antibodies against exogenously administered factor VIII (FVIII) or FIX, which leaves patients unresponsive to FVIII or FIX preparations and vulnerable to bleeding. FVIIa-based bypassing agents, which include recombinant human (rh)FVIIa and plasmaderived activated prothrombin complex concentrates, were specifically developed to achieve hemostasis in hemophilic patients with inhibitors since supraphysiological levels of FVIIa can rescue bleeding episodes based on direct activation of FX via tissue factor (TF)-dependent pathways or independently of TF on the surface of platelets [1, 2] .
Unfortunately, treatment with FVIIa-based bypassing agents remains suboptimal [3, 4] , and alternative treatment strategies to provide more sustained thrombin formation are therefore desirable. Several different strategies have been proposed, including novel FVIIa variants with increased catalytic activity and half-life [5, 6] , engineered FIX molecules with enhanced ability to bind and activate FX [7] , and engineered zymogen-like FXa variants that become active on engaging activated FV (FVa) in the prothrombinase complex [8, 9] . As an alternative to these protease-based strategies, modulation of FVa cofactor activity may be another attractive strategy to enhance thrombin generation and to improve hemostasis in hemophilia.
FV circulates in plasma at a concentration of2 0 nmol L À1 (~10 lg mL À1 ), with a half-life of 12-36 h.
As an important cofactor in the prothrombinase complex, FVa can enhance the rate of thrombin generation1 0 000-fold [10, 11] . However, the cofactor function of FVa is closely regulated by proteolytic inactivation of FVa by activated protein C (APC). APC rapidly inactivates FVa via proteolytic cleavage at Arg506, followed by a slower cleavage at Arg306 [12] . Mutations of these inactivation cleavage sites, such as Arg506Gln (a.k.a. FV Leiden ), extend the FVa cofactor activity half-life, thereby augmenting its ability to enhance thrombin generation. Experimental in vitro and in vivo studies strongly suggest a disease-modifier effect of APC-resistant FV mutations in hemophilia. For instance, APC-resistant FV mutants (FV Leiden and FV Cambridge [Arg306Thr]) showed enhanced thrombin generation in hemophilic plasma compared with wild-type FV [13, 14] , and hemophilic mice with the FV Leiden mutation showed improved activated partial thromboplastin time (APTT) clotting profiles and laser-induced microvascular hemostasis compared with hemophilic mice with normal FV [15] . Furthermore, there is increasing clinical consensus that bleeding is attenuated in hemophiliacs with the FV Leiden mutation since population studies indicate improved outcome measures such as factor concentrate consumption, annual bleeding episodes, and joint damage [16] . On the other hand, infusion of FVa achieved only a very modest shortening of the APTT in hemophilia B and, although FV Leiden homozygosity reduced blood loss after tail transsection in hemophilia B mice, it failed to do so in hemophilia A mice [15] . Thus, these observations support the investigation of a pharmacological approach to 'FVa activity augmentation' in hemophilia and provide unique opportunities for molecular engineering of FVa to increase its efficacy by enhancing its activity and stability. Several years ago, we engineered an interdomain disulfide bond (His609Cys-Glu1691Cys) in FV connecting the A2 and A3 domains (A2-SS-A3) to study the discriminative contributions of A2 domain dissociation vs. proteolytic inactivation by APC to FVa inactivation [12] . Anchoring the A2 domain to the FVa molecule conveyed a significant resistance to APC-mediated inactivation similar to that of the Leiden (Arg506Gln) mutation. Furthermore, the interdomain disulfide bond seemed to enhance the specific activity of FVa [12] . These observations prompted the current investigation to determine the potential of FVa(A2-SS-A3) either alone or in combination with APC-cleavage site mutations as a novel approach of 'FVa activity augmentation' to correct hemostasis in hemophilia.
Materials and methods

Materials
Plasma purified prothrombin, thrombin, and FXa were obtained from Enzyme Research Laboratories (South Bend, IN, USA). Hirudin was from Calbiochem (La Jolla, CA, USA), and corn trypsin inhibitor was obtained from Haematologic Technologies (Essex Junction, VT, USA). Substrates Pefachrome TH and Z-Gly-Gly-Arg-AMC were from Centerchem (Norwalk, CT, USA) and Bachem (Torrance, CA, USA), respectively. Human FVIII-or FV-deficient plasma was purchased from George King Bio-Medical (Overland Park, KS, USA). Phospholipid vesicles (80% phosphatidylcholine, 20% phosphatidylserine) were prepared as described previously [17] .
Recombinant FV mutants
Recombinant wild-type FV and FV mutants were made on a B-domain deleted S2183A platform and purified from conditioned media of stable transfected BHK cells through a combination of affinity chromatography using anti-FV 3B1 and HV5101 monoclonal antibodies as described previously [12, 18] . FV protein concentration was determined based on absorbance at 280 nm using FV e 1% = 15.4 [19] 
Prothrombinase assays
Prothrombinase assays were performed as described previously [12] . Briefly, FVa and phospholipid vesicles were mixed, and 15 lL aliquots were added to 10 lL of FXa, followed by 10 lL of prothrombin in prothrombinase buffer ( ), thrombin formation was assessed by measuring the change in absorbance at 405 nm using a VersaMax Microplate reader (Molecular Devices, Sunnyvale, CA, USA).
Thrombin generation assays
Endogenous thrombin potential (ETP) assays were performed as described previously [20] . ) and incubated at 37°C for 1 min, followed by the addition of 50 lL of Innovin â . The clotting times were recorded using an ST4 coagulometer (Diagnostica Stago, Parsippany, NJ, USA).
Animals
All described animal protocols were carried out as approved by the institutional animal and care committee of The Scripps Research Institute. Several breeding pairs of FVIII-deficient mice (BalbC background) were a generous gift of Dr. David Lillicrap. Mice of both sexes, aged ≥ 8 weeks, were used for tail bleeding assays.
Bleeding assays in FVIII-deficient mice
Mice were anesthetized and placed on temperature-controlled heating pads (37°C), and the distal portion of the tail was cut at 1.5-mm diameter (moderate hemostatic challenge), after which the tail was immersed in a predefined volume of 37°C saline (0.9% NaCl) for 20 min. To study effects on bleeding and clot stability, tubes were changed after 10 min to collect blood for the first and second 10 min separately. Blood loss was determined by the hemoglobin concentration in the saline solution after red cell lysis with 2% acetic acid and measured by absorbance at 405 nm. Using a hemoglobin standard derived from defined blood volumes, blood loss was calculated assuming a hematocrit of 46% and expressed in microliter per gram body weight. Groups of FVIII-deficient mice were injected intravenously (retro-orbital) within 2 min before the tail cut with equal volumes (200 lL) of wildtype FVa, super FVa, 50 units kg À1 FVIII (Kogenate â ; Bayer Healthcare), or saline. All agents were diluted in sterile sodium chloride 0.9% for injection (Hospira Inc., San Diego, CA, USA). As with FVIII, FVa variant dosing was based on prothrombinase cofactor activity, whereby the activity of 20 nmol L À1 wild-type FVa (approximate FV plasma concentration) was defined as 1 unit. In experiments where data were expressed as percent bleed protection, mice were considered protected if blood loss was below the mean blood loss plus 3 SDs observed in wild-type BalbC mice [23] .
Statistical analysis
Student's t test or for bleeding, Kruskal-Wallis followed by one-tailed Mann-Whitney test was used to assess statistical significance where appropriate. Differences in percent bleed protection were evaluated with Fisher's exact test. A P-value of ≤ 0.05 was considered statistically significant.
Results
To enhance the biologic stability of disulfide-stabilized [12, 24, 25] .
Activity of FVa variants in vitro
After purification, all FVa mutants appeared homogeneous (> 90%) and showed identical band patterns and activation cleavage rates on reduced SDS-PAGE gel (Figure S2 ). Cofactor activities of FVa and the FVa mutants were determined using a prothrombinase (IIase) assay with purified components. (Fig. 1A) .
Increases in specific activity of FVa mutants generally correlated with enhanced functional activity of these mutants in thrombin generation assays in FV-deficient plasma (Fig. 1B) . Dose-response titration of wild-type FVa in FV-deficient plasma indicated half-maximal normalization of thrombin generation at 0. (Fig. 1B,C) . Interestingly, mutation of APC cleavage sites, either Arg506Gln in FVa Leiden (A2-SS-A3) or all three in super FVa, resulted in a significant improvement of thrombin generation compared with FVa(A2-SS-A3). Reconstitution of wild-type FVa or super FVa in FV-deficient plasma at 2.5% of normal FV levels resulted in normalization of the APTT and near normalization of the PT clotting times by superFVa, whereas only a partial correction was observed by wild-type FVa (Fig. 2) . Thus, stabilization of the A2 interaction with the A3 domain by introduction of a disulfide bridge results in a FVa with significantly increased cofactor activity in purified prothrombinase assays, in plasma in APTT and PT clotting assays and in thrombin generation assays.
A2-A3 disulfide formation and APC-resistance of super FVa
To confirm the formation of the disulfide bridge in superFVa and verify its resistance to proteolysis by APC, both wild-type FV (Fig. 3A ) and super FV (Fig. 3B ) were analyzed by Western blot. After activation by thrombin, the heavy chain of FVa shifted down and APC generated the typical 1-506, 1-306, and 307-506 heavy chain fragments under both nonreducing and reducing conditions as anticipated. The heavy chain of super FVa also shifted down after activation by thrombin, but the mobility of super FVa (~190 kDa) was lower than that of the FVa heavy chain, consistent with a disulfide bond connecting the heavy and light chain. The usual heavy chain band became apparent under reducing conditions. However, some heavy chain band was also present in super FVa under nonreducing conditions, indicating that the disulfide bond was not formed in~15% of the super FVa molecules ( Figure S3 ). Reflecting the APC cleavage site mutations, no 1-506, 1-306, or 307-506 heavy chain fragments were observed in super FVa upon incubation with APC under either nonreducing or reducing conditions. Western blot revealed an additional~150-kDa band of minor abundance, which is likely due to proteolysis of FV in the conditioned media and during purification despite the presence of protease inhibitors.
Compared with FVa(A2-SS-A3), incubation of FVa Leiden (A2-SS-A3) with APC retained~50% cofactor activity in purified prothrombinase assays, whereas the cofactor activity of super FVa (> 90%) was not affected by APC (Fig. 3C) . Similar results were obtained for the inactivation of wild-type FVa and super FVa by mouse APC ( Figure S4 ). To address the APC resistance of super FVa in plasma, FV-deficient plasma and FVIII-deficient plasma were reconstituted with super FVa and thrombin generation was determined in the presence of increasing concentrations of APC. The ability of super FVa to support thrombin formation was fully retained in the presence of APC, whereas the APC dose-dependently inhibited thrombin generation in the presence of wild-type FVa. At the highest concentration of APC (10 nmol L À1 ), the mean ETP was reduced to~20% with wild-type FVa, whereas the mean ETP with super FVa remained at~100% (Fig. 3D,  E) .
Improved thrombin generation in FVIII-deficient plasma by super FVa
To address the potential of super FVa as a bypassing agent in hemophilia A, thrombin generation was determined in ) of the normal FV plasma concentration. Wild-type FVa had a minor but statistically significant effect on thrombin generation (Fig. 4A ) and increased the ETP by4 0% (Fig. 4B) . FVa(A2-SS-A3) and FVa Leiden (A2-SS-A3) also enhanced the ETP in FVIII-deficient plasma by 40-50% (Fig. 4B) . However, super FVa resulted in a pronounced increase of ETP (~2-fold greater than wild-type FVa). While super FVa normalized the ETP in FVIII-deficient plasma to that of normal plasma or FVIII-deficient plasma reconstituted with 1 U mL À1 FVIII (Fig. 4B) , the shape of the ETP curve remained noticeably different (Fig. 4A ).
Efficient treatment of acute tail bleeding in FVIII-deficient mice by super FVa
To determine the in vivo efficacy of super FVa for bleed reduction in hemophilia, blood loss was determined in a tail transsection model in FVIII-deficient mice. Blood was collected separately for the first 10 min and second 10-20 min after the tail clip to distinguish initial bleeding from late rebleeding that typically occurs in FVIII-deficient mice 8-10 min after initial tail clip. (Fig. 6A) . Results for the combined 20-min bleeding period were similar (Fig. 6B) FVa was less efficient than FVIII in decreasing blood loss during the second 10 min, the difference in mean blood loss for the combined 20-min bleeding period was not statistically significant (9.7 lL g À1 FVIII vs. 15.6 lL g À1 super FVa at 5 units; P = 0.12) (Fig. 6B) . Notably, only treatment with super FVa at a high dose (5 units) achieved significant percent bleed protection comparable to that achieved by FVIII during the combined 20-min bleeding period (Table 1) . Thus, super FVa decreased both initial bleeding and late rebleeding in FVIII-deficient mice. 
Discussion
Here, we explored FVa activity augmentation as a potential therapeutic approach to reduce bleeding in hemophilia using an engineered FVa variant, named super FVa, in which an interdomain disulfide bond that covalently anchored the A2 to the A3 domain (A2-SS-A3) provided increased cofactor activity, while mutations of the APC cleavage sites enhanced its biologic stability [12, 26] .
Because B-domain deleted FV has some inherent cofactor activity, only FVa variants were compared. Furthermore, it was previously reported that clot formation with human plasma-derived FV in FVIII-deficient mice required prior activation of the FV [15] . FVIII-deficient mice typically have delayed rebleeding episodes that are not observed in normal mice. To distinguish initial bleeding from late rebleeding, blood was collected separately for the first 10 min and then for 10-20 min after the tail clip, based on time course analysis of bleeding indicating that in FVIII-deficient mice late rebleeding generally occurred 8-10 min after the initial tail clip. Both FVa variants were able to reduce initial bleeding in FVIII-deficient mice, but correction with wild-type FVa was less efficient than with super FVa. In fact, wild-type FVa resulted in blood loss reduction only during the first 10 min at a 2.5-fold higher dose compared with super FVa and had no effects on late rebleeding. In contrast, treatment with super FVa reduced blood loss due to late rebleeding during the second 10 min and resulted in significant blood loss reduction and bleed protection during the combined 20-min bleeding period.
Attempts to explain how and why super FVa improved bleeding in hemophilia raised several interesting questions regarding the structure and function of FVa, its interactions with FXa, and the inferred contributions of APC's anticoagulant activity to bleeding in hemophilia. All FVa variants containing the A2-A3 domain disulfide showed increased specific activity, but the mechanism for this remains unclear. Mechanisms for thrombin generation by the prothrombinase complex are multifaceted and involve two cleavages in prothrombin at Arg271 and Arg320. In defining the ordered conversion of prothrombin to thrombin, some define the mechanism as 'channeling,' a process in which intermediate forms of cleaved prothrombin are not released from the prothrombinase complex, while others argue in favor of 'ratcheting' that involves conformational changes in the enzyme and/or substrate to allow for sequential cleavage [27, 28] . Recent structural insights into the prothrombinase complex place FXa along the C1-A3-A2 axis of FVa with the protease domain of FXa binding to interface between the A2 and A3 domain and with the protease domain of prothrombin docking on the ledge formed by the A1 and A2 domain of FVa [29] . Thus, the A2-SS-A3 disulfide can conceivably contribute to promote prothrombinase complex interactions, as well as facilitate conformational flexibility of FXa and/or the substrate as it transitions from prothrombin to meizo- Percent bleed protection referred to the percentage of mice demonstrating blood loss below a threshold defined as mean blood loss plus 3 SDs in wild-type BalbC mice. For the 10-or 20-min time points, mice were considered protected if blood loss was ≤ 9.9 or ≤ 19.5 lL g À1 , respectively. Comparisons between groups that attained statistical significance are marked by the same specific symbols (all P ≤ 0.02).
thrombin after cleavage at Arg320 to reposition Arg271 to the active site of FXa. One plausible mechanism for the enhanced activity of the A2-SS-A3 disulfide could involve changes in the rate of prothrombin cleavage at Arg 320 vs. Arg271, thereby enhancing the relative formation of meizothrombin. An increased formation of meizothrombin vs. prethrombin 2 would be consistent with enhanced activity of A2-SS-A3 containing FVa in purified prothrombinase assays and with increased thrombin formation in plasma via feedback activation of the intrinsic pathway since FXI is activated more efficiently by meizothrombin than by thrombin [30] . The enhanced thrombin generation by super FVa compared with wild-type FVa in hemophilia A plasma in vitro can be attributed to the increased specific activity of super FVa due to the A2-SS-A3 disulfide. However, in vivo comparison of super FVa to wild-type FVa was based on dosing by equal activity units, and thus the higher specific activity of super FVa cannot explain the more efficient bleed reduction. Therefore, we propose that the APC cleavage site mutations in super FVa resulting in resistance to APCmediated proteolysis are responsible for its favorable hemostatic properties in vivo. Contributions of APC-resistance to improved hemostasis in hemophilia were also implied by previous observations in which the transgenic expression of FV Leiden provided partial improvements of hemostasis in hemophilia mice [15] . Furthermore, thrombin generation in hemophilia plasma was enhanced when APC-resistant Arg506Gln and Arg306Thr mutations in FV were combined [13] or when APC was inhibited by low molecular weight inhibitors [31] [32] [33] . Mutations at all three APC inactivation sites render super FVa completely resistant to inactivation by APC, and these APC-resistant properties of super FVa likely provide important contributions to its increased in vivo efficacy to improve hemostasis in hemophilia. Implicit in these observations is a potentially important but incompletely understood contribution of the protein C system to bleeding in hemophilia that deserves further investigation.
In summary, the results of our studies provide proof of concept that 'FVa activity augmentation' can improve hemostasis in hemophilia and reduce rebleeding. Molecular engineering of FVa overcame the limitations associated with wild-type FVa activity augmentation by targeting its biological efficacy via the introduction of APC resistance and by targeting its pharmacologic efficacy via the introduction of the A2-SS-A3 disulfide. Our results warrant further characterization of the potential therapeutic benefits of super FVa as a novel bypassing agent, including circulating half-life, thrombogenicity, and immunogenicity studies. 
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